Sage Therapeutics (SAGE) : The consensus on Sage Therapeutics (SAGE) based on 6 analyst recommendation on the company stock is 1.83, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 4 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 analyst believes that the stock is a Buy, which can produce decent returns in the future. 1 analyst sees the stock overvalued at current levels and advises a Strong Sell on the stock.
Sage Therapeutics (SAGE) : The highest short term price target forecast on Sage Therapeutics (SAGE) is $95 and the lowest target price is $18. A total of 6 equity analysts are currently covering the company. The average price of all the analysts is $69 with a standard deviation of $28.96.
Also, BMO Capital initiates coverage on Sage Therapeutics (NASDAQ:SAGE) The current rating of the shares is Outperform. The rating by the firm was issued on June 29, 2016.
Sage Therapeutics (NASDAQ:SAGE): After opening at $41.86, the stock dipped to an intraday low of $41.17 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $43.5 and the buying power remained strong till the end. The stock closed at $43.26 for the day, a gain of 4.02% for the day session. The total traded volume was 736,027. The stocks close on the previous trading day was $41.59.
SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat life-threatening, rare central nervous system (CNS) disorders. The Companys lead product candidate in its status epilepticus (SE) program is SAGE-547. SAGE-689 and SAGE-217 are two additional product candidates in its pipeline. The Company has submitted investigational new drug (IND) for SAGE-547 for the treatment of SRSE with the United States Food and Drug Administration. SAGE-547 is an allosteric modulator of both synaptic and extra-synaptic GABAA receptors. SAGE-217 is a neuroactive steroid that acts as a positive allosteric modulator of synaptic and extra-synaptic GABAA receptor subtypes. SAGE-689 is being developed as an adjunctive IV therapy for the treatment of status epilepticus patients.